Prevention of HBV Reinfection in Perioperative Period of Liver Transplantation_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Ning , DOU Kefeng

The Xijing Hospital of The Fourth Military Medical University, Xi’an 710032, China;

Corresponding author：

Keywords：

Liver transplantation; Hepatitis B virus; Hepatitis B immune globulin; LamivudineAdefovir

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To investigate the prevention of HBV reinfection in the perioperative period of liver transplantation on HBV-related diseases．
Methods 　Published papers were collected and reviewed．
Results 　HBV-related diseases were the main indications of liver transplantation．The prevention for HBV reinfection affects the survivals remarkably. Nowadays, a lot of medication have been used in the prevention of HBV reinfection， and the therapeutic regimens were different from each other.
Conclusion 　Liver transplantation is an effective treatment for HBV-related disease． Appropriate prevention of HBV reinfection in the perioperative period of liver transplantation is important for the survivals of patients．

Citation： ZHANG Ning,DOU Kefeng. Prevention of HBV Reinfection in Perioperative Period of Liver Transplantation. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2007, 14(6): 735-738. doi: Copy

1.	Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease [J]. Hepatology, 2002; 35(6)∶1528.
2.	Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort [J]. Hepatology, 2001; 34(2)∶411.
3.	Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B [J]. Hepatology, 2001; 33(2)∶424.
4.	Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B [J]. Hepatology, 2000; 31(1)∶207.
5.	Lo CM, Cheung ST, Lai CL, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis [J]. Ann Surg, 2001; 233(2)∶276.
6.	Perillo RP. Potential importance of the sexual transmission of non-A, non-B hepatitis [J]. Hepatology, 1991; 13(4)∶805.
7.	Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy [J]. Gastroenterology, 2002; 123(3)∶719.
8.	Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [J]. Gastroenterology, 2004; 126(1)∶91.
9.	Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients [J]. Hepatology， 2003; 38(6)∶1419.
10.	Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adevir in a liver transplantation patient [J]. J Hepalo, 2003; 39(6)∶1085.
11.	Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks [J]. Hepatology， 2002; 36(2)∶464〖HJ*2〗12　Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis [J]. Lancet， 1996; 348(9036)∶1212.
12.	严茂林, 严律南，李波，等. 拉米夫定对肝移植术后乙肝病毒再感染的预防作用 [J]. 中国普外基础与临床杂志， 2006； 13（2）∶205.
13.	Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient [J]. Gut， 2000; 46(1)∶107.
14.	Wai CT, Prabhakaran K, Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant [J]. Transplant Proc, 2004; 36(8)∶2313.
15.	Palumbo E. Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil [J]. Recenti Prog Med, 2007; 98(4)∶237.
16.	Barcena R, Del Campo S, Moraleda G, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus [J]. Transplant Proc, 2005; 37(9)∶3960.
17.	Yoshida H, Kato T, Levi DM, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection [J]. Clin Transplant, 2007; 21(2)∶166.
18.	Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen [J]. N Engl J Med, 1993; 329(25)∶1842.
19.	Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis [J]. Hepatology, 2003; 38(1)∶86.
20.	Devlin J, Smith HM, O’Grady JG, et al. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients [J]. J Hepatol, 1994; 21(2)∶204.
21.	Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin [J]. Hepatology, 1996; 24(6)∶1327.
22.	Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin [J]. Hepatology, 1998; 28(2)∶555.
23.	Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review [J]. Hepatology, 2000; 32(6)∶1189.
24.	Mentha G, Giostra E, Negro F, et al. High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation [J]. Transplant Proc, 1997; 29(5)∶2369.
25.	Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation [J]. Clin Liver Dis, 2003; 7(3)∶537.
26.	Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [J]. Liver Transpl, 2000; 6(4)∶429.
27.	Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin [J]. Dig Dis Sci, 2007; 52(10)∶2497.
28.	Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation [J]. Gastroenterology, 2002; 122(2)∶264.
29.	Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation [J]. Liver Transpl, 2000; 6(4)∶434.
30.	Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation [J]. J Hepatol, 2001; 34(6)∶888.
31.	Neff GW, O’brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade [J]. Liver Transpl, 2004; 10(11)∶1372.

1. 　Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease [J]. Hepatology, 2002; 35(6)∶1528.
2. 　Yao FY, Terrault NA, Freise C, et al. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort [J]. Hepatology, 2001; 34(2)∶411.
3. 　Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B [J]. Hepatology, 2001; 33(2)∶424.
4. 　Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B [J]. Hepatology, 2000; 31(1)∶207.
5. 　Lo CM, Cheung ST, Lai CL, et al. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis [J]. Ann Surg, 2001; 233(2)∶276.
6. 　Perillo RP. Potential importance of the sexual transmission of non-A, non-B hepatitis [J]. Hepatology, 1991; 13(4)∶805.
7. 　Fontana RJ, Hann HW, Perrillo RP, et al. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy [J]. Gastroenterology, 2002; 123(3)∶719.
8. 　Peters MG, Hann Hw H, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [J]. Gastroenterology, 2004; 126(1)∶91.
9. 　Schiff ER, Lai CL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients [J]. Hepatology， 2003; 38(6)∶1419.
10. 　Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adevir in a liver transplantation patient [J]. J Hepalo, 2003; 39(6)∶1085.
11. 　Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks [J]. Hepatology， 2002; 36(2)∶464〖HJ*2〗12　Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis [J]. Lancet， 1996; 348(9036)∶1212.
12. 　严茂林, 严律南，李波，等. 拉米夫定对肝移植术后乙肝病毒再感染的预防作用 [J]. 中国普外基础与临床杂志， 2006； 13（2）∶205.
13. 　Mutimer D, Pillay D, Shields P, et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient [J]. Gut， 2000; 46(1)∶107.
14. 　Wai CT, Prabhakaran K, Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant [J]. Transplant Proc, 2004; 36(8)∶2313.
15. 　Palumbo E. Recent advances in the treatment of the hepatitis HBV-related. Effectiveness and tolerability of adefovir dipivoxil [J]. Recenti Prog Med, 2007; 98(4)∶237.
16. 　Barcena R, Del Campo S, Moraleda G, et al. Study on the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus [J]. Transplant Proc, 2005; 37(9)∶3960.
17. 　Yoshida H, Kato T, Levi DM, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection [J]. Clin Transplant, 2007; 21(2)∶166.
18. 　Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen [J]. N Engl J Med, 1993; 329(25)∶1842.
19. 　Roche B, Feray C, Gigou M, et al. HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis [J]. Hepatology, 2003; 38(1)∶86.
20. 　Devlin J, Smith HM, O’Grady JG, et al. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg-positive liver recipients [J]. J Hepatol, 1994; 21(2)∶204.
21. 　Terrault NA, Zhou S, Combs C, et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin [J]. Hepatology, 1996; 24(6)∶1327.
22. 　Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin [J]. Hepatology, 1998; 28(2)∶555.
23. 　Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review [J]. Hepatology, 2000; 32(6)∶1189.
24. 　Mentha G, Giostra E, Negro F, et al. High-titered anti-HBs fresh frozen plasma for immunoprophylaxis against hepatitis B virus recurrence after liver transplantation [J]. Transplant Proc, 1997; 29(5)∶2369.
25. 　Terrault NA, Vyas G. Hepatitis B immune globulin preparations and use in liver transplantation [J]. Clin Liver Dis, 2003; 7(3)∶537.
26. 　Angus PW, McCaughan GW, Gane EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [J]. Liver Transpl, 2000; 6(4)∶429.
27. 　Neff GW, Kemmer N, Kaiser TE, et al. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin [J]. Dig Dis Sci, 2007; 52(10)∶2497.
28. 　Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation [J]. Gastroenterology, 2002; 122(2)∶264.
29. 　Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation [J]. Liver Transpl, 2000; 6(4)∶434.
30. 　Naoumov NV, Lopes AR, Burra P, et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation [J]. J Hepatol, 2001; 34(6)∶888.
31. 　Neff GW, O’brien CB, Nery J, et al. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade [J]. Liver Transpl, 2004; 10(11)∶1372.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Prevention of HBV Reinfection in Perioperative Period of Liver Transplantation

Abstract Full text Figures/Tables Video References Cited by

Format

Content